Subscribe

DCI Blog

All
All

Duke Cancer Institute (DCI) Blog provides updates, organizational announcements, the latest in funding opportunities and information on upcoming conferences and symposiums. This blog also highlights inspiring patient stories and the accomplishments and achievements of DCI faculty and staff. Subscribers are invited to submit story ideas and other news of interest. Email submissions and feedback to Karen E. Butler, Director of Communications, Duke Cancer Institute.

Kirsch Leads First Trial of Immune Checkpoint Inhibitors For Non-Metastatic Sarcoma

A multi-institutional team of researchers led by Duke Cancer Institute (DCI) radiation oncologist David Kirsch, MD, PhD, has been awarded an eight-year, $2.5 million grant from Stand Up to Cancer . The funds support a clinical trial to investigate the efficacy of treatment of patients with high-...

Patz’s Human-Derived Antibody Treatment Moves Forward

Patz's Human-Derived Antibody Treatment Moves Forward With Boost from NCI and Manufacturing Agreement Grid Therapeutics, LLC, a new start-up company led by Duke Cancer Institute cardiothoracic radiologist Edward Patz, Jr., MD , has developed and is on track to manufacture and bring to trial what it...

Hanks Team Awarded $500,000 to Study Immunotherapy Resistance

A team of Duke Cancer Institute researchers led by Brent Hanks, MD, PhD, has been awarded a two-year, $500,000 grant from Merck & Co., Inc., to investigate clinical biomarkers of immunotherapy resistance in melanoma. Hanks is the principle investigator of the group that includes Bala...

Gold Nanostars and Immunotherapy Vaccinate Mice Against Cancer

By combining an FDA-approved cancer immunotherapy with an emerging tumor-roasting nanotechnology, Duke University researchers improved the efficacy of both therapies in a proof-of-concept study using mice. The potent combination also attacked satellite tumors and distant cancerous cells, completely...

Immunotherapy Target Suppresses Pain to Mask Cancer

Once hailed as a breakthrough in cancer treatment, immunotherapies are now raising concerns as doctors note new side effects like severe allergic reactions, acute-onset diabetes and heart damage. These drugs, which work by unleashing the immune system to fight cancer, are only effective in about a...

Teacher, Melanoma Survivor, Thanks Her DCI “Dragonslayer”

Fourth grade teacher Tricia Gallagher was 43 when she felt something like a scab — smaller than a sunflower seed — on her head. She didn’t think much of it. “I thought it was a tick, because my boys and I hike,” said the energetic mother of two active teenagers. Her doctor in Winston Salem, North...

Immunotherapy for Glioblastoma Well Tolerated; Survival Gains Observed  

A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination to be well tolerated while also resulting in unexpectedly significant survival increases, researchers at the Duke Cancer Institute...

Antibody Preferentially Attacks Cancer Cells

A research team from Duke Health has developed an antibody from the body’s own immune system that preferentially attacks cancer cells. The antibody works by targeting a natural defense mechanism that cancer tumors exploit. Cells in the body essentially use a home security system that relies on...